TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.55
-0.44 (-1.19%)
At close: 4:00PM EDT

36.55 0.00 (0.00%)
After hours: 4:34PM EDT

Stock chart is not supported by your current browser
Previous Close 36.99
Open 37.12
Bid 36.54 x 1100
Ask 36.53 x 900
Day's Range 35.29 - 37.78
52 Week Range 24.21 - 58.56
Volume 396,868
Avg. Volume 245,523
Market Cap 1.188B
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -5.25
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 60.57
Trade prices are not sourced from all markets
  • GlobeNewswire

    Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor

    SAN DIEGO, Sept. 30, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

  • Is Failure in Store for the WeWork IPO?
    InvestorPlace

    Is Failure in Store for the WeWork IPO?

    WeWork parent The We Company has delayed the office-sharing startup's initial public offering until the end of the year. It now either won't come to the public market at all, or come at such a low valuation its venture backers will take a loss. This isn't terribly unusual for 2019.Source: Mitch Hutchinson / Shutterstock.com So far in 2019 there have been 94 IPOs, and 38 of them have shown negative returns.The big winners, like CrowdStrike Holdings (NASDAQ:CRWD), Beyond Meat (NASDAQ:BYND) and Zoom Video Telecommunications (NASDAQ:ZM), have generally come to the market prepared to make a profit. There have also been big medical winners with market caps near $1 billion, like ShockWave Medical (NASDAQ:SWAV) and Turning Point Therapeutics (NASDAQ:TPTX). Most IPOs are still hits -- but the batting average is declining like an aging slugger's.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWeWork is distinguished by the same flaws as Uber (NYSE:UBER) stock and Lyft (NASDAQ:LYFT) stock. It's not making money, even at scale, and current investors are looking at you for a bailout. The WeWork ProblemWeWork's model is to buy lots of office space, fix it up, then sell it at retail in the form of "memberships." As I wrote in August, it's more like LA Fitness than Cloudflare (NYSE:NET), which went public Sept. 13 and is already showing a 25% return. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Worse, WeWork's business model is not unique. IWG (OTCMKTS:IWGFF), founded in Belgium back in 1989, has been operating in low-cost suburban office parks for years. It came public at the end of 2016 and only proved itself this year. IWGFF stock is up 92% year-to-date.The difference is that IWG has a market cap of $4.8 billion. WeWork was initially seeking a market cap of $47 billion. Worse, WeWork needs the $3 billion it was trying to raise in order to secure the $6 billion line of credit in order to keep operating.The business model is based on a myth of young workers with startups signing up for prestige "co-working spaces" dressed up with amenities they like. In fact, WeWork has mainly signed up established tech companies seeking contingency space like Salesforce (NYSE:CRM), Cisco (NASDAQ:CSCO) and Facebook (NASDAQ:FB). It's expansion insurance. CEO Adam NeumannMeanwhile t-shirted CEO Adam Neumann has come off as something of a fraud. He isn't a dweeby kid. He's a 40-year old Israeli military veteran who spent big money before earning a dime for shareholders. He tried to score $5.9 million from his own company for trademarking the word "We." This is also a mom-and-pop operation; co-founder Miguel McKelvey gets only six mentions in the U.S. Securities and Exchange Commission Form S-1, against 20 mentions for Neumann's wife Rebekah.While portraying a handsome young family man on TV, Neumann also created a fraternity culture that drew a sexual harassment suit last year.Worse, it's clear the business model is not yet working. WeWork lost $1.9 billion in 2018, then another $904 million for the first six months of 2019, on revenue of $1.5 billion. The Bottom Line on the WeWork IPOThe real loser is SoftBank (OTCMKTS:SFTBF) and its Vision Fund. It brought $100 billion to the party in order control the technology of the future -- and it's trying to raise another $100 billion. SoftBank founder Masayoshi Son runs the fund, but the money is mostly from sovereign wealth funds in Saudi Arabia and the United Arab Emirates.Son's losers, in addition to WeWork, include Uber, Sprint (NYSE:S) and Slack (NYSE:WORK), which is down more than 30% after coming public in June. Son has called his Vision Fund the ultimate disruptor, but it may be Son who turns out to be the greater fool.Dana Blankenhorn is a financial and technology journalist. He is the author of the mystery thriller, The Reluctant Detective Finds Her Family, available at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Is Failure in Store for the WeWork IPO? appeared first on InvestorPlace.

  • GuruFocus.com

    Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $450,000 ...

    President & CEO of Turning Point Therapeutics Inc (30-Year Financial, Insider Trades) Athena Countouriotis (insider trades) bought 10,000 shares of TPTX on 09/10/2019 at an average price of $45 a share. Continue reading...

  • Benzinga

    Short Squeeze Candidates: 10 Most Heavily Shorted Stocks

    Short squeezes can be one of the most powerful trading catalysts on Wall Street, and traders are always on the lookout for the next major short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky just ...

  • GlobeNewswire

    Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its public offering of 4,500,000 shares of common stock at a price to the public of $45.00 per share. The gross proceeds to the company from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $202.5 million.  In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. Goldman Sachs & Co. LLC and SVB Leerink are acting as joint book-running managers for the offering.

  • GlobeNewswire

    Turning Point Therapeutics Announces Proposed Public Offering of Common Stock

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced today it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 4,500,000 shares of common stock. The company also intends to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined.

  • GlobeNewswire

    Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor

    In TKI-naïve ROS1+ NSCLC Patients, Overall Response Rate by Blinded Review Improved to 91 Percent; Median Duration of Response Not Yet Mature with 20.1 months of Median.

  • 3 New Biotech Stocks That Keep On Soaring
    Motley Fool

    3 New Biotech Stocks That Keep On Soaring

    Can their share prices continue to climb?

  • GlobeNewswire

    Turning Point Therapeutics Participate in Upcoming Investor Conferences

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in the 2019 Wells Fargo Healthcare Conference and Citi’s 14th Annual Biotech Conference on Sept. 4-5 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

  • GlobeNewswire

    Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results

    FDA Accepts Repotrectinib Recommended Phase 2 Dose Regimen for Registrational TRIDENT-1 Study Two Abstracts Selected for Presentation at the European Society for Medical.

  • What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register?
    Simply Wall St.

    What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register?

    If you want to know who really controls Turning Point Therapeutics, Inc. (NASDAQ:TPTX), then you'll have to look at...

  • GlobeNewswire

    Turning Point Therapeutics’ CEO to Present at Canaccord Genuity 39th Annual Growth Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the 39th Annual Canaccord Genuity Growth Conference on Aug. 8 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of a Phase 1 clinical study of patients with advanced solid tumors harboring genetic alterations in MET. “We believe the precision therapies we are designing and developing have potential to assist many patients with oncogenic driven cancers, making the start of this new clinical study an important step toward that goal,” said Athena Countouriotis, M.D, chief executive officer of Turning Point Therapeutics.

  • GlobeNewswire

    Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today named Yi Larson as executive vice president and chief financial officer, effective Aug. 26. Ms. Larson joins the company from Goldman Sachs & Co. where she worked for more than 12 years and most recently served as managing director of Healthcare Investment Banking. “Yi brings an important new dimension to our growing team from her experience advising biotechnology companies through more than $100 billion in financing and strategic transactions,” said Athena Countouriotis, M.D, president and chief executive officer.

  • GlobeNewswire

    Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Carol Gallagher, Pharm.D. to its board of directors. Dr. Gallagher brings nearly 30 years of biotech leadership, board and investing experience, currently serving as a partner for New Enterprise Associates (NEA). “Carol has nurtured the growth of many biotechnology companies during her distinguished career as both an operating executive and board member,” said Dr. Sheila Gujrathi, chair of the Turning Point Therapeutics board.

  • GlobeNewswire

    Turning Point Therapeutics to Host Second Quarter 2019 Conference Call

    SAN DIEGO, July 22, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, will report.

  • GlobeNewswire

    Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients with ROS1+ advanced non-small cell lung cancer and TRK+ advanced solid tumors. Patients will be treated with Turning Point’s lead investigational kinase inhibitor, repotrectinib, which has been studied in more than 80 patients in the ongoing Phase 1 portion of the study.

  • GlobeNewswire

    Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Goldman Sachs 40th Annual Global Healthcare Conference on June 11 in Rancho Palos Verdes, Calif. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer

    In TKI-naïve ROS1+ Patients, Overall Response Rate by Blinded Review is 82 Percent, and 83 Percent at Likely Recommended Phase 2 Dose of 160 mg QD or Above; Median Duration of.

  • GlobeNewswire

    Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor

    The study is designed to assess the safety, tolerability, and preliminary clinical activity of TPX-0022 at escalating doses in patients with advanced or metastatic solid tumors harboring genetic alterations in MET. TPX-0022 has been designed to target MET-driven tumor cells, and also modulate the tumor microenvironment by inhibition of CSF1R. “The clearance of our IND for TPX-0022 is another important milestone toward our goal to bring a new class of precision therapies to patients,” said Athena Countouriotis, M.D., president and chief executive officer.

  • GlobeNewswire

    Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the UBS Global Healthcare Conference on May 21 in New York. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • GlobeNewswire

    Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the appointment of Patrick Machado, J.D. to its board of directors. Mr. Machado brings more than 20 years of biotech management and board experience, including as co-founder and chief business and financial officer of Medivation, Inc. “Pat has built a strong reputation in the biotech and broader business community for the tremendous value he has added at multiple companies throughout his career,” said Athena Countouriotis, M.D, president and chief executive officer.

  • GlobeNewswire

    Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, and Almac Diagnostic Services, a global stratified medicine company, today announced approval by the U.S. Food and Drug Administration (FDA) of an investigational device exemption (IDE) for the diagnostic assay that will be used in Turning Point’s registrational phase 2 clinical study. The next-generation sequencing (NGS) assay is intended for use in identifying patients with ROS1, NTRK1-3 and ALK gene fusions in advanced solid tumors. Clinical investigators will use the diagnostic test to determine molecular eligibility for enrollment into Turning Point’s registrational Phase 2 portion of the global TRIDENT-1 clinical study.